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OBJECTIVES The present analysis examines the prognostic implications of moderate renal insufficiency in
patients with asymptomatic and symptomatic left ventricular systolic dysfunction.
BACKGROUND Chronic elevations in intracardiac filling pressures may lead to progressive ventricular dilation
and heart failure progression. The ability to maintain fluid balance and prevent increased
intracardiac filling pressures is critically dependent on the adequacy of renal function.
METHODS This is a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD)
Trials, in which moderate renal insufficiency is defined as a baseline creatinine clearance
,60 ml/min, as estimated from the Cockroft-Gault equation.
RESULTS In the SOLVD Prevention Trial, multivariate analyses demonstrated moderate renal
insufficiency to be associated with an increased risk for all-cause mortality (Relative Risk [RR]
1.41; p 5 0.001), largely explained by an increased risk for pump-failure death (RR 1.68;
p 5 0.007) and the combined end point death or hospitalization for heart failure (RR 1.33;
p 5 0.001). Likewise, in the Treatment Trial, multivariate analyses demonstrated moderate
renal insufficiency to be associated with an increased risk for all-cause mortality (RR 1.41;
p 5 0.001), also largely explained by an increased risk for pump-failure death (RR 1.49;
p 5 0.007) and the combined end point death or hospitalization for heart failure (RR 1.45;
p 5 0.001).
CONCLUSIONS Even moderate degrees of renal insufficiency are independently associated with an increased
risk for all-cause mortality in patients with heart failure, largely explained by an increased risk
of heart failure progression. These data suggest that, rather than simply being a marker of the
severity of underlying disease, the adequacy of renal function may be a primary determinant
of compensation in patients with heart failure, and therapy capable of improving renal
function may delay disease progression. (J Am Coll Cardiol 2000;35:681–9) © 2000 by the
American College of Cardiology
The adequacy of renal function is of central importance to
the syndrome of congestive heart failure (1). The prognostic
implications of moderate renal insufficiency in patients with
heart failure, in particular those patients with asymptomatic
left ventricular dysfunction, are not well described. Impaired
renal function may be associated with adverse outcomes in
heart failure because it is a marker for patients with more
severe heart failure or a greater burden of coexistent disease.
However, it is possible that the presence of renal insuffi-
ciency may have a causal role in progression of heart failure.
We conducted a retrospective analysis of participants in
the Studies of Left Ventricular Dysfunction (SOLVD)
Prevention and Treatment Trials (2,3) to: 1) determine the
frequency of moderate renal insufficiency in patients with
asymptomatic and symptomatic moderate to severe left
ventricular dysfunction, 2) test the hypothesis that moderate
renal insufficiency might be independently associated with
progression of heart failure, and 3) test the hypothesis that
moderate renal insufficiency might be independently asso-
ciated with all-cause mortality.
METHODS
Design of the SOLVD trials. The SOLVD Prevention
and Treatment Trials were designed to study the effect of
enalapril on survival in patients with asymptomatic and
symptomatic heart failure, respectively. There were 4,228
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participants in the Prevention Trial, designed to include
patients with asymptomatic left ventricular systolic dysfunc-
tion, although close to one-third of the participants were
classified as New York Heart Association (NYHA) class II.
There were 2,569 participants in the SOLVD Treatment
Trial, which consisted uniformly of symptomatic left ven-
tricular dysfunction, predominantly NYHA class II and III.
To be eligible for participation in either trial, the patients
were required to have a recently documented ejection
fraction #35%. Participants were randomized to the
angiotensin-converting enzyme inhibitor enalapril or pla-
cebo. Exclusion criteria included: active angina pectoris
requiring surgical intervention, unstable angina, myocardial
infarction within one month, renal failure (defined as a
creatinine value .2.0 mg/dl) or severe pulmonary disease.
The design and rationale for these trials has been previously
described (4).
Determination of renal function. All participants had a
baseline creatinine value obtained as part of the screening
process to determine eligibility. The baseline creatinine
value in the SOLVD participants was determined when the
potential participants were considered clinically stable;
therefore, it did not reflect, if elevated, decompensated heart
failure. Patients with a creatinine value .2 mg/dl (177
mmol/liter) were excluded from each of the SOLVD Trials.
However, there were some patients with a creatinine value
.2 mg/dl (177 mmol/liter). This included 23 patients
randomized in the Prevention Trial and 22 participants
randomized in the Treatment Trial with a baseline creati-
nine between 2 and 2.2 mg/dl. These participants were
included in this analysis.
The creatinine clearance (CrCl) was estimated for each
participant according to the Cockroft-Gault equation using
the baseline weight and serum creatinine in each partici-
pant. For men, the CrCl was estimated as follows: CrCl 5
([140 2 age in years] 3 weight in kg)/(72 3 creatinine in
mg/dl). For women, the value of CrCl was multiplied by
0.85, as specified in the Cockroft-Gault equation.
For the purposes of our primary analysis, we defined
“moderate” renal insufficiency as an estimated CrCl
,60/ml/min before data analysis. In addition, the associa-
tion of renal insufficiency with the risk for progression of
heart failure and mortality would be explored for other
values of estimated CrCl, including an analysis of the
estimated baseline CrCl in each participant as a continuous
variable. Our predefined definition of moderate renal insuf-
ficiency (CrCl #60 ml/min) represented a 27% decrease
from the average CrCl for the entire cohort in the SOLVD
Prevention Trial and a 5% decrease from the average CrCl
for the entire cohort in the SOLVD Treatment Trial.
Definitions of end points. For this analysis, we defined
pump-failure death to include “pump-failure” as classified
by the SOLVD investigators, as well as those deaths
classified as “arrhythmic with some antecedent worsening
heart failure.” We defined arrhythmic death to include only
those deaths classified by the SOLVD investigators as
“arrhythmic with no antecedent worsening heart failure.”
We predefined two measures of the rate of progression of
left ventricular systolic dysfunction, whether asymptomatic
or symptomatic, to include the risk for: 1) pump-failure
death, and 2) the composite end point, death (all-cause
mortality) or hospitalization for heart failure. The risk for
each event was assessed using a Cox-proportional hazards
model to adjust for differences in time to each event.
Data collection, definitions and statistical methods.
Baseline data were collected at the time of enrollment into
either of the SOLVD trials. Group comparisons of contin-
uous data used Student t test, assuming unequal variances in
the comparison groups when appropriate. Group compari-
sons of categorical data used the chi-squared statistic. A p
value #0.05 was considered statistically significant. Kaplan-
Meier survival curves were constructed comparing patients
with and without renal insufficiency in each trial and
formally compared using the log-rank statistic.
For the multivariate analyses, age and left-ventricular
ejection fraction (LVEF) were analyzed as continuous
variables. The following variables were analyzed as dichot-
omous (yes/no) variables: diabetes, prior hypertension, prior
angina, prior stroke. The etiology of left ventricular dys-
function was also analyzed as a dichotomous variable,
comparing patients classified with an ischemic etiology to
those classified with a nonischemic etiology of left ventric-
ular dysfunction. The severity of clinical symptoms, as
assessed by the NYHA classification scheme, was also
adjusted for as a dichotomous variable: NYHA class II
versus class I in the Prevention Trial and NYHA class
III/IV with NYHA class I/II in the Treatment Trial.
Medication use was determined at baseline in each
participant. The following medications were adjusted for in
the analyses as dichotomous (yes/no) variables, indicating
the use or non-use of the medication: antiplatelet agents,
diuretics, antiarrhythmic drugs and digoxin. We also ad-
justed according to randomization assignment to enalapril
or placebo.
Univariate and multivariate relationships were investi-
gated using a Cox proportional-hazards model; two-sided
95% confidence intervals (CIs) were constructed around
each point estimate of relative risk (RR) and a p value #0.05
was considered statistically significant. In the multivariate
Abbreviations and Acronyms
BUN 5 blood urea nitrogen
CI 5 confidence interval
CrCl 5 creatinine clearance
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
RR 5 relative risk
SOLVD 5 Studies of Left Ventricular Dysfunction
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analyses, the following covariates were adjusted for: age,
gender, LVEF, NYHA functional class, prior hypertension,
diabetes, stroke, etiology (ischemic vs. nonischemic), use of
antiplatelet agents, antiarrhythmic drugs, diuretics, digoxin
and randomization to enalapril or placebo. Statistical anal-
yses were conducted using the Statistical Analysis Software
(SAS) version 6.12 (Cary, North Carolina).
RESULTS
Baseline characteristics. The baseline characteristics in
participants with a CrCl ,60 ml/min compared with those
with a CrCl $60 ml/min are displayed in Table 1. In each
trial, the participants with moderate renal insufficiency
(CrCl ,60 ml/min) had more advanced symptoms of heart
failure, as measured by the NYHA class, but there was no
significant difference in the average LVEF between the two
groups. Prior hypertension and nonfatal strokes were more
common in each trial in the patients with moderate renal
insufficiency. There were no significant differences between
the groups in either trial in the prevalence of prior myocar-
dial infarction, the assignment of an ischemic etiology as the
primary cause of left ventricular function or diabetes. The
average blood urea nitrogen (BUN)/creatinine ratio was
lower in the group with moderate renal insufficiency in the
Prevention Trial, and there was no significant difference in
the BUN/creatinine ratio in the two groups in the Treat-
ment Trial.
Causes of death in each group. (Table 2). PREVENTION
TRIAL. In the Prevention Trial, the participants with mod-
erate renal insufficiency (CrCl ,60 ml/min) experienced
greater all-cause mortality (22.1% vs. 13.6%), pump-failure
death (7.5% vs. 3.7%) and the composite end point death or
hospitalization for worsening heart failure (30.7% vs. 20.4%
[all log-rank p values ,0.001]) compared with those with-
out. There were more arrhythmic deaths in the group with
renal insufficiency (6.1% vs. 4.5%, p 5 0.03).
TREATMENT TRIAL. In the Treatment Trial, the partici-
pants with moderate renal insufficiency (CrCl ,60 ml/min)
demonstrated greater all-cause mortality (47% vs. 32.9%),
pump-failure death (24.1% vs. 15.6%) and the combined
end point death or hospitalization for heart failure (61.8%
vs. 48.5% [all log-rank p values ,0.001]). However, in the
SOLVD Treatment Trial, there was no significant differ-
ence in arrhythmic deaths in those with (CrCl ,60 ml/min)
and without (CrCl $60 ml/min) mild renal insufficiency,
respectively (8.8% vs. 8.6%, p 5 0.47).
Univariate analysis. PREVENTION TRIAL. In the Preven-
tion Trial, univariate analyses demonstrated that moderate
renal insufficiency was associated with an increased risk for
Table 1. Baseline Characteristics According to Baseline Creatinine Clearance in the SOLVD Prevention and Treatment Trials
Prevention Trial Treatment Trial
CrCl < 60
(N 5 757)
CrCl > 60
(N 5 2,916)
CrCl < 60
(N 5 772)
CrCl > 60
(N 5 1,389)
Age, mean (SD) 67.7 (6.8) 57.0 (9.9)*** 66.7 (7.5) 57.4 (9.6)***
Men (%) 81.0 91.1*** 73.7 85.8***
Ejection fraction, mean (SD) 28.2 (5.9) 28.3 (5.6) 24.4 (6.6) 24.8 (6.8)
CrCl, mean (SD) 51.4 (24.3) 91.7 (24.2) 50.0 (9.0) 90.1 (24.6)
Creatinine [mg/dl], mean (SD) 1.4 (0.3) 1.1 (0.2)*** 1.4 (0.3) 1.1 (0.2)***
BUN/creatinine ratio (SD) 15.0 (4.6) 15.4 (5.0)* 16.3 (5.4) 15.8 (5.5)†
Sodium, mean, (SD) 140.1 (3.1) 140.2 (2.8) 139.4 (3.5) 139.7 (3.1)†
NYHA III/IV (%) — — 38.8 29.9***
NYHA II (%) 39.0 32.9** 52.3 58.9***
NYHA I (%) 61.0 67.1** 8.9 11.2
Presence of: (%)
Diabetes 14.1 15.1 25.4 24.6
Prior hypertension 42.8 35.1*** 42.8 39.0†
Ischemic etiology 84.9 82.8 72.2 70.5
Nonischemic etiology 15.1 17.2 27.8 29.5
Prior MI 79.9 80.6 67.0 65.4
Prior stroke 9.0 5.2*** 9.1 6.6*
Use of: (%)
Antiplatelet agent 50.1 55.0* 35.2 33.1
Digoxin 15.5 12.4* 68.8 68.5
Diuretic 21.5 15.8*** 87.3 82.3**
Antiarrhythmic agent 19.7 13.9*** 26.2 20.4**
Randomization to enalapril 51.1 49.6 48.2 51.4
BUN 5 blood urea nitrogen; CrCl 5 creatinine clearance; GFR 5 glomerular filtration rate; MI 5 myocardial infarction; NYHA 5 New York Heart Association.
*p # 0.05 and . 0.01; **p # 0.01 and . 0.001; ***p # 0.001; †p . 0.05 and # 0.1.
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all-cause mortality (RR 1.78; 95% CI 1.48 to 2.13; p 5
0.0001), pump-failure death (RR 2.22; 95% CI 1.61 to 3.07;
p 5 0.0001), arrhythmic death (RR 1.47; 95% CI 1.05 to
2.06; p 5 0.02) and the combined end point death or
hospitalization for worsening heart failure (RR 1.65; 95%
CI 1.42 to 1.92; p 5 0.0001). When the estimated CrCl
was analyzed as a continuous variable in univariate analysis,
it also was significantly associated with an increased risk for
all-cause mortality (RR per 30 ml/min decrease in CrCl
1.42; 95% CI 1.27 to 1.58; p 5 0.0001). Other variables in
the SOLVD Prevention Trial associated with an increased
risk for all-cause mortality on univariate analysis included:
age, ejection fraction, a higher NYHA functional class,
diabetes, prior stroke, a history of hypertension and the
baseline use of any antiarrhythmic agent, diuretics and
digoxin. Variables associated with a decreased all-cause
mortality risk included: use of antiplatelet agents and an
ischemic etiology of left ventricular dysfunction.
TREATMENT TRIAL. In the Treatment Trial, univariate
analyses demonstrated that moderate renal insufficiency was
associated with an increased risk for all-cause mortality (RR
1.59; 95% CI 1.38 to 1.82; p 5 0.0001), pump-failure death
(RR 1.73; 95% CI 1.42 to 2.10; p 5 0.0001) and the
combined end point death or hospitalization for worsening
heart failure (RR 1.49; 95% CI 1.33 to 1.68; p 5 0.0001)
but not arrhythmic death (RR 1.12; 95% CI 0.83 to 1.51;
p 5 0.48). When the estimated CrCl was analyzed as a
continuous variable in univariate analysis, it was significantly
associated with an increased risk for all-cause mortality (RR
per 30 ml/min decrease in CrCl 1.15; 95% CI 1.08 to 24;
p 5 0.0001) Other variables in the SOLVD Treatment
Trial associated with an increased risk for all-cause mortality
on univariate analysis included: age, ejection fraction, a
greater NYHA functional class, diabetes and baseline use of
antiarrhythmic agents, diuretics and digoxin. Those associ-
ated with a decreased all-cause mortality risk included: use
of antiplatelet agents and randomization to enalapril.
Multivariate analyses. PREVENTION TRIAL. In the Preven-
tion Trial (Table 3), despite multivariate adjustment for
differences in disease severity, comorbidities and baseline
medication use, moderate renal insufficiency remained in-
dependently associated with an increased risk for all-cause
mortality (RR 1.41; 95% CI 1.15 to 1.74; p 5 0.001),
pump-failure death (RR 1.68; 95% CI 1.16 to 2.44; p 5
0.007) and the composite end point of death or hospital-
ization for heart failure (RR 1.33; 95% CI 1.12 to 1.59; p 5
0.001) but not arrhythmic death (RR 1.27; 95% CI 0.87 to
1.87; p 5 0.22). When the CrCl was analyzed as a
continuous variable in multivariate analyses, a decline in
CrCl remained significantly associated with an increased
risk for all-cause mortality (RR, per 30 ml/min decrease in
CrCl, 1.24; 95% CI 1.09 to 1.42; p 5 0.001), pump-failure
death (RR, per 30 ml/min decrease in CrCl, 1.33; 95% CI
1.05 to 1.71; p 5 0.02) and the combined outcome of death
or hospitalization for heart failure (RR, per 30 ml/min
decrease in CrCl, 1.23; 95% CI 1.10 to 1.36; p 5 0.0002)
but not arrhythmic death (p 5 0.26).
TREATMENT TRIAL. In the Treatment Trial (Table 4),
multivariate analyses demonstrated that moderate renal
Table 2. Causes of Death According to Baseline Renal Function
Prevention Trial (N 5 3,673)
CrCl < 60 ml/min CrCl > 60 ml/min
Cumulative (%) Incidence* Cumulative (%) Incidence* p Value†
Total mortality 22.1 8.2 13.6 4.6 ,0.001
Pump failure death 7.5 2.8 3.7 1.3 ,0.001
Arrhythmic death 6.1 2.2 4.5 1.5 0.03
Myocardial infarction 2.6 0.8 2.4 1.0 0.44
Other 5.9 2.4 3.0 0.8
Death or Hosp for CHF‡ 30.7 11.3 20.4 7.0 ,0.001
Treatment Trial (N 5 2,161)
CrCl < 60 ml/min CrCl > 60 ml/min
Cumulative (%) Incidence* Cumulative (%) Incidence* p Value†
Total mortality 47.0 18.7 32.9 11.7 ,0.001
Pump failure death 24.1 9.6 15.6 5.6 ,0.001
Arrhythmic death 8.8 3.5 8.6 3.1 0.47
Myocardial infarction 4.0 1.6 4.4 1.6 0.91
Other 10.1 4.0 4.3 1.4
Death or Hosp for CHF 61.8 24.6 48.5 17.3 ,0.001
CHF 5 congestive heart failure; CrCl 5 creatinine clearance; Hosp 5 hospitalization.
*The incidence is unadjusted and expressed as the rate per 100 participant-years of follow-up; †p value based upon the log-rank statistic; ‡combined end point of death or
hospitalization for heart failure.
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insufficiency was associated with an increased risk for
all-cause mortality (RR 1.41; 95% CI 1.20 to 1.65; p 5
0.0001), pump-failure death (RR 1.49; 95% CI 1.19 to 1.86;
p 5 0.0005) and the composite end point of death or
hospitalization for heart failure (RR 1.45; 95% CI 1.27 to
1.67; p 5 0.0001) but not arrhythmic death (RR 1.17; 95%
CI 0.83 to 1.64; p 5 0.37). When CrCl was entered as a
continuous variable, adjusting for the same variables, a
decline in CrCl remained significantly associated with an
increased risk for all-cause mortality (RR, per 30 ml/min
decrease in CrCl, 1.22; 95% CI 1.11 to 1.35; p 5 0.0001),
pump-failure death (RR, per 30 ml/min decrease in CrCl,
1.21; 95% CI 1.05 to 1.40; p 5 0.009) and the combined
outcome of death or hospitalization for heart failure (RR,
per 30 ml/min decrease in CrCl, 1.12; 95% CI 1.04 to 1.22;
p 5 0.007). There was a trend for an increased risk for
arrhythmic death (RR, per 30 ml/min decrease in CrCl,
1.20; 95% CI 0.97 to 1.47; p 5 0.08).
Table 3. Results of Multivariate Analyses in the SOLVD Prevention Trial
All-Cause Mortality Pump-Failure Death Death or Hosp. for CHF
RR (95% CI) RR (95% CI) RR (95% CI)
CrCl (,60 vs. $60 ml/min) 1.41 (1.15–1.74)*** 1.68 (1.16–2.44)** 1.33 (1.12–1.59)***
Age, per 5 year increase 1.09 (1.04–1.14)*** 1.12 (1.02–1.22)** 1.08 (1.04–1.13)***
EF, per 10% decrease 1.45 (1.27–1.65)*** 1.58 (1.25–2.02)*** 1.49 (1.34–1.68)***
Men vs. women 1.28 (0.97–1.70)† 1.17 (0.71–1.90) 1.13 (0.90–1.40)
NYHA II vs. I 1.10 (0.93–1.31) 1.42 (1.04–1.94)* 1.20 (1.04–1.38)*
Presence of:
Prior stroke 1.78 (1.36–2.33)*** 1.35 (0.79–2.31) 1.65 (1.30–2.08)***
Prior hypertension 1.18 (0.97–1.41)† 1.15 (0.82–1.63) 1.08 (0.92–1.26)
Ischemic vs. nonischemic 0.90 (0.72–1.12) 0.77 (0.52–1.14) 0.77 (0.65–0.92)**
Diabetes 1.29 (1.04–1.61)* 1.45 (0.98–2.14)† 1.51 (1.27–1.80)***
Use of:
Diuretic 1.30 (1.06–1.61)* 1.28 (0.87–1.89) 1.26 (1.06–1.51)**
Antiarrhythmic drug 1.09 (0.87–1.36) 1.13 (0.76–1.69) 1.10 (0.91–1.32)
Antiplatelet agent 0.88 (0.74–1.05) 0.97 (0.70–1.34) 0.84 (0.72–0.97)*
Digoxin 1.21 (0.97–1.52)† 1.36 (0.92–2.01) 1.12 (0.93–1.35)
Randomization to enalapril 0.96 (0.81–1.13) 0.81 (0.56–1.10) 0.82 (0.74–0.98)*
CI 5 confidence interval; CrCl 5 creatinine clearance; EF 5 ejection fraction; Hosp. 5 hospitalization; NYHA 5 New York Heart Association class.
*p # 0.05 and . 0.01; **p # 0.01 and . 0.001; ***p # 0.001; †p . 0.05 and # 0.1.
Table 4. Results of Multivariate Analyses in the SOLVD Treatment Trial
All-Cause Mortality Pump-Failure Death Death or Hosp. for CHF
RR (95% CI) RR (95% CI) RR (95% CI)
CrCl (,60 vs. $60 ml/min) 1.41 (1.20–1.65)*** 1.49 (1.19–1.86)*** 1.45 (1.27–1.67)***
Age, per 5 year increase 1.04 (1.00–1.08)† 1.04 (0.98–1.10) 0.99 (0.96–1.03)
EF, per 10% decrease 1.45 (1.30–1.58)*** 1.62 (1.40–1.87)*** 1.28 (1.18–1.40)***
Men vs. women 1.25 (1.04–1.51)* 1.12 (0.87–1.44) 1.25 (1.07–1.46)**
NYHA III/IV vs. I/II 1.57 (1.36–1.80)*** 2.01 (1.65–2.46)*** 1.63 (1.45–1.84)***
Presence of:
Prior stroke 1.07 (0.83–1.39) 1.15 (0.80–1.63) 1.15 (1.00–1.31)
Prior hypertension 1.06 (0.92–1.22) 1.08 (0.88–1.32) 1.08 (0.95–1.22)
Ischemic vs. nonischemic 1.05 (0.90–1.24) 0.89 (0.71–1.11) 0.94 (0.82–1.07)
Diabetes 1.24 (1.06–1.45)** 1.33 (1.07–1.66)* 1.32 (1.16–1.51)***
Use of:
Diuretic 1.24 (1.00–1.53)* 1.24 (0.91–1.70) 1.41 (1.18–1.69)***
Antiarrhythmic drug 1.27 (1.09–1.49)** 1.38 (1.10–1.72)** 1.21 (1.06–1.39)**
Antiplatelet agent 0.85 (0.72–0.99)* 0.85 (0.67–1.08) 0.84 (0.73–0.96)
Digoxin 1.37 (1.17–1.61)*** 1.70 (1.33–2.17)*** 1.14 (1.00–1.31)*
Randomization to enalapril 0.82 (0.72–0.95)** 0.80 (0.66–0.98)* 0.71 (0.63–0.79)***
CHF 5 congestive heart failure; CI 5 confidence interval; CrCl 5 creatinine clearance; EF 5 ejection fraction; Hosp. 5 hospitalization; NYHA 5 New York Heart Association
class.
*p # 0.05 and . 0.01; **p # 0.01 and . 0.001; ***p # 0.001; †p . 0.05 and # 0.1.
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Risk associated with degree of renal insufficiency. Table
5 displays the risk for all-cause mortality, pump-failure
death and the combined end point (death or hospitalization
for worsening heart failure) associated with varying degrees
of renal insufficiency. As demonstrated in each trial, even a
CrCl #70 ml/min was associated with a significant increase
in mortality risk. In the Prevention Trial, the risk for
mortality and disease progression clearly increases as the
severity of renal insufficiency increases. In the Treatment
Trial, a similar trend is demonstrated, except for the group
with a CrCl #40 ml/min.
Differences in baseline potassium and calcium channel-
blocker use. We also conducted an analysis that adjusted
for baseline serum potassium, in addition to the other
variables. Despite doing so, moderate renal insufficiency
(CrCl ,60 ml/min) remained associated with an increased
risk for mortality in the Prevention (RR 1.43; 95% CI 1.16
to 1.77; p 5 0.0008) and Treatment (RR 1.42; 95% CI 1.21
to 1.66; p 5 0.0001) Trials. Finally, despite adjusting for
differences in the use of calcium channel blockers, which
was more frequent in the participants with moderate renal
insufficiency, the presence of moderate renal insufficiency
remained independently associated with an increased risk
for all-cause mortality in the Prevention (RR 1.34; 95% CI
1.11 to 1.63; p 5 0.003) and Treatment Trials (RR 1.29;
95% CI 1.12 to 1.49; p 5 0.0005).
Results in Prevention Trial participants not using diuret-
ics at baseline. We conducted an analysis limited to the
3,050 SOLVD Prevention Trial participants not using any
type of diuretic at baseline. In this cohort, a CrCl
,60 ml/min, compared with a CrCl $60 ml/min, was
associated with an increased risk for all-cause mortality on
univariate analysis (RR 1.66; 95% CI 1.34 to 2.06; p 5
0.0001). Upon multivariate analysis, a CrCl ,60 ml/min in
the patients not using diuretics at baseline remained inde-
pendently associated with an increased risk for all-cause
mortality (RR 1.33; 95% CI 1.04 to 1.70; p 5 0.02) and
trends for an increased risk for pump-failure death (RR
1.42; 95% CI 0.91 to 2.21; p 5 0.11) and the combined end
point of death or heart failure hospitalization (RR 1.20; 95%
CI 0.98–1.47; p 5 0.08).
Adjusting for differences in the discontinuation of study
drug. PREVENTION TRIAL. We conducted a multivariate
analysis that only included the participants in the SOLVD
Prevention Trial who did not discontinue use of the study
drug enalapril. In this analysis, the participants with mod-
erate renal insufficiency were at increased risk for all-cause
mortality (RR 1.52; 95% CI 1.19 to 1.95; p 5 0.0009),
Table 5. Risk Associated With Various Degrees of Renal Insufficiency
Prevention Trial (Mean CrCl 5 82 6 26.9 ml/min)
Group 1 vs. Group 2
CrCl (Total in Group 1)
ACM
RR (95% CI)
Pump Failure
RR (95% CI)
Death or CHF
Hosp.
RR (95% CI)
,70 vs. $70 ml/min
(1,354 participants)
1.27 (1.05–1.54) 1.40 (0.98–1.98) 1.21 (1.03–1.41)
,60 vs. $60 ml/min
(757 participants)
1.41 (1.15–1.74) 1.68 (1.16–2.44) 1.33 (1.12–1.59)
,50 vs. $50 ml/min
(313 participants)
1.60 (1.23–2.08) 1.68 (1.05–2.67) 1.59 (1.28–1.98)
,40 vs. $40 ml/min
(100 participants)
2.00 (1.37–2.94) 2.70 (1.46–5.00) 2.13 (1.55–2.92)
Treatment Trial (Mean CrCl 5 73.7 6 27.5 ml/min)
Group 1 vs. Group 2
CrCl (Total in Group 1)
ACM
RR (95% CI)
Pump Failure
RR (95% CI)
Death or CHF
Hosp.
RR (95% CI)
,70 vs. $70 ml/min
(1,093 participants)
1.18 (1.01–1.39) 1.19 (0.95–1.20) 1.24 (1.08–1.42)
,60 vs. $60 ml/min
(772 participants)
1.41 (1.20–1.65) 1.49 (1.19–1.86) 1.45 (1.27–1.67)
,50 vs. $50 ml/min
(421 participants)
1.47 (1.23–1.75) 1.49 (1.16–1.91) 1.34 (1.15–1.57)
,40 vs. $40 ml/min
(143 participants)
1.30 (1.01–1.67) 1.32 (0.93–1.89) 1.32 (1.05–1.65)
ACM 5 all-cause mortality; CI 5 two-sided 95% confidence interval; CrCl 5 creatinine clearance (estimated using the Cockroft-Gault equation); RR 5 relative risk.
*The relative risk and two-sided 95% confidence intervals for various dichotomized values of estimated glomerular filtration rate after Cox proportional-hazards regression
analysis, adjusting for same covariates as the main analysis: age, ejection fraction, NYHA functional class, prior hypertension, diabetes, prior stroke, etiology of left ventricular
dysfunction, gender, baseline use of diuretics, antiplatelet agent, any antiarrhythmic or digoxin and randomization to placebo or enalapril.
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pump-failure death (RR 2.21; 95% CI 1.38 to 3.54; p 5
0.0009) and the combined end point death or hospitaliza-
tion for heart failure (RR 1.43; 95% CI 1.16 to 1.78; p 5
0.001).
TREATMENT TRIAL. In the SOLVD Treatment Trial, the
drop-out rate from protocol therapy was not significantly
greater in those with moderate renal insufficiency (CrCl
,60 ml/min) compared with those without (CrCl
$60 ml/min) (37.8 vs. 35%, p 5 0.23). The results of
multivariate analyses limited to the SOLVD Treatment
Trial participants remaining on protocol therapy demon-
strated that moderate renal insufficiency remained indepen-
dently associated with an increased risk for all-cause mor-
tality (RR 1.39; 95% CI 1.17 to 1.67; p 5 0.0003),
pump-failure death (RR 1.45; 95% CI 1.12 to 1.88; p 5
0.005) and the combined end point of death or hospitaliza-
tion for worsening heart failure (RR 1.54; 95% CI 1.31 to
1.82; p 5 0.0001).
Consistency of findings across subgroups. We conducted
stratified multivariate analyses within subgroups. There was
a consistent and independent association of moderate renal
insufficiency with an increased risk for all-cause mortality in
the patients with a prior history of hypertension (RR 1.52;
95% CI 1.25 to 1.83; p 5 0.001) as well as those partici-
pants without (RR 1.34; 95% CI 1.14 to 1.59; p 5 0.0006),
participants with an ischemic etiology of left ventricular
dysfunction (RR 1.32; 95% CI 1.14 to 1.52; p 5 0.0002)
and those participants with a nonischemic etiology of left
ventricular dysfunction (RR 1.75; 95% CI 1.36 to 2.27; p 5
0.0001), participants with diabetes (RR 1.87; 95% CI 1.46
to 2.39; p 5 0.0001) as well as those without diabetes (RR
1.29; 95% CI 1.11 to 1.49; p 5 0.007). Moderate renal
insufficiency remained associated with an increased risk for
mortality in those participants randomized to treatment
with angiotensin-converting enzyme inhibitor (RR 1.53;
95% CI 1.27 to 1.83; p 5 0.0001) or placebo (RR 1.33; 95%
CI 1.12 to 1.58; p 5 0.002).
DISCUSSION
These data suggest that impaired renal function is indepen-
dently associated with all-cause mortality in patients with
mild to moderate heart failure and that even moderate
degrees of renal impairment are of prognostic importance in
patients with asymptomatic and symptomatic left ventricu-
lar systolic dysfunction. The association of moderate renal
insufficiency with an increased risk for pump failure death
and the composite end point of death or hospitalization for
heart failure suggests that moderate renal dysfunction is
independently associated with an increased risk for heart
failure progression. In particular, it appears that the ade-
quacy of renal function is important in delaying progression
of asymptomatic or mildly symptomatic left ventricular
dysfunction.
Potential mechanisms of the increased mortality in pa-
tients with renal insufficiency. MARKER FOR MORE SEVERE
HEART FAILURE. The patients with moderate renal insuffi-
ciency did have evidence of more severe left ventricular
dysfunction and a greater prevalence of comorbidities.
However, moderate renal insufficiency remained indepen-
dently associated with adverse outcomes despite adjusting
for these differences. The increased creatinine that accom-
panies worsening heart failure is often thought to represent
prerenal azotemia and is associated with an increased
BUN/creatinine ratio. Interestingly, in the SOLVD Pre-
vention Trial, the average BUN/creatinine ratio for the
participants with moderate renal insufficiency was slightly,
but significantly, lower than those without. In the Treat-
ment Trial, there was no significant difference in the average
BUN/creatinine ratio for those with and without moderate
renal insufficiency.
GREATER PREVALENCE OF COEXISTENT DISEASE. The
treatment of the comorbid diseases that may have caused the
renal insufficiency may have influenced outcomes. For
example, hypertension and the use of calcium-channel
blockers were more common in the patients with renal
insufficiency. Some data suggest that calcium-channel
blockers may be associated with adverse outcomes in pa-
tients with ischemic cardiomyopathy (5,6), in particular
those with reduced ejection fractions. Nonetheless, adjust-
ing for differences in the use of calcium channel blockers at
baseline did not reduce the association of renal dysfunction
with an increased risk for mortality.
DIFFERENCES IN DISCONTINUATION OF ANGIOTENSIN
CONVERTING ENZYME INHIBITOR THERAPY. The partici-
pants with baseline renal insufficiency may have been more
likely to require discontinuation of enalapril due to worsen-
ing renal function, and this may have accounted for the
increased mortality. To explore this, we studied the prog-
nostic implications of moderate renal insufficiency in those
patients who did not discontinue use of enalapril after
randomization into the SOLVD Trials. In these partici-
pants, moderate renal insufficiency remained independently
associated with an increased risk for all-cause mortality,
pump-failure death and the combined end point death or
heart failure hospitalization.
CAUSAL RELATIONSHIP DUE TO CARDIORENAL INTERAC-
TION. It is reasonable to consider the hypothesis that
moderate renal insufficiency may be causally related to a
greater rate of progression of left ventricular systolic dys-
function and increased mortality risk. There are experimen-
tal data suggesting that moderate renal insufficiency may
play a causative role in progression to symptomatic heart
failure. For example, in a canine model (7) of pacing-
induced asymptomatic left ventricular dysfunction, CrCl,
sodium excretion and the natriuretic response to volume
expansion were preserved despite reductions in cardiac
output, mean arterial blood pressure and elevations in
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systemic vascular resistance, plasma norepinephrine and
atrial natriuretic factor. In early LV dysfunction, normally
functioning kidneys are able to maintain sodium balance
and prevent volume expansion. An impairment in renal
function may lead to sodium and fluid retention, increases in
cardiac filling pressures and progressive ventricular dilation.
Comparison with prior studies. In a study (8) of 190 heart
failure patients with a mean LVEF of 30% and NYHA class
II–III symptoms, two-year mortality was 32% and serum
creatinine was one of seven independent predictors of
mortality. Patients with a creatinine value .121 mmol/liter
had a 2.9 fold increased risk of death compared with
patients with lower creatinine values. In another study (9),
the clinical findings related to prognosis were prospectively
examined in 300 outpatients with heart failure diagnosed on
case history data, LVEF #40% or a cardiothoracic ratio
$50%. The baseline characteristics of survivors and non-
survivors after one year (16% mortality) were compared.
The mean creatinine of those who died was 108 6
20.1 mmol/liter compared with 105.8 6 27.7 mmol/liter in
survivors. The relative risk of death was calculated at 2.03
for those with higher creatinine values. Other more com-
mon prognostic factors were not analyzed. In the
PROMISE Study (10), which assessed the long-term effi-
cacy of milrinone in 1,088 patients with heart failure
followed for a median of 6.1 months, patients with a
baseline creatinine .1.3 mg/dl treated with milrinone
demonstrated a trend for an increased risk for mortality (RR
1.32; 95% CI 0.98–1.78; p 5 0.06) compared with those
with a creatinine #1.3 mg/dl. Abnormal renal function as
measured by an elevated creatinine was independently
associated with the development of heart failure in a
case-control study of hypertensive Nigerian patients, despite
group matching on important variables such as age, gender,
level of blood pressure and body mass index as well as
adjustment for hypertensive fundal changes (11).
Study limitations. Medication use was determined at base-
line, and it is likely to have changed during the course of the
SOLVD Trials. Despite adjusting for potentially confound-
ing explanatory variables, all retrospective analyses are lim-
ited by the potentially confounding influence of variables we
did not account for as well as residual confounding from
variables that we did adjust for. There is likely to be
misclassification of specific modes of death in the heart
failure population (12), which is why we defined all-cause
mortality as a primary end point. Finally, in our estimation
of CrCl using the Cockroft-Gault equation, we used the
baseline weight of each participant. The Cockroft-Gault
equation is based upon ideal body weight and is not
validated in patients with heart failure. It is likely that the
baseline weight in some of the participants, in particular
those in the SOLVD Treatment Trial, was greater than
ideal weight due to fluid retention. However, this would
lead to an overestimation of CrCl since the weight is in the
numerator of the Cockroft-Gault equation. Therefore, if
the patients with most severe heart failure were indeed more
likely to have baseline weights above ideal, the direction of
the bias would be in the opposite direction from the results
demonstrated in this analysis.
Clinical implications. These data suggest that moderate
renal insufficiency is common even in patients with absent
to mild symptoms of heart failure and may itself lead to a
greater risk for progression of heart failure as well as overall
mortality. This implies that therapy capable of improving or
stabilizing renal function may improve prognosis in patients
with heart failure. Thus, we hope that these data will
support future research aimed at elucidating the pathophys-
iology leading to renal insufficiency in heart failure and a
better understanding of the mechanisms of the cardiorenal
interaction.
Conclusions. Moderate renal insufficiency is indepen-
dently associated with an increased risk for all cause mor-
tality and heart failure progression in patients with asymp-
tomatic and symptomatic left ventricular systolic
dysfunction. Rather than simply being a marker of disease
severity, these data suggest that moderate renal insufficiency
may be causally related to an increased risk for mortality and
progression of heart failure.
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